Characterization of human IgG1 monoclonal antibody against gangliosides expressed on tumor cells

Hybridoma

Volumn 17, Issue 2, 1998, Pages 133-142

  Mukerjee, Sonjoy ^a   Nasoff, Marc ^a   McKnight, Michael ^a   Glassy, Mark ^a  

^a Novopharm Biotech Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; ARTICLE; CANCER PATIENT; CELL ADHESION; CELL GROWTH; CHO CELL; ENZYME IMMUNOASSAY; GENE EXPRESSION REGULATION; IMMUNE RESPONSE; LYMPHOBLASTOID CELL; NONHUMAN; PRIORITY JOURNAL; TARGET CELL; TUMOR CELL CULTURE;

ANIMALIA; CRICETINAE; CRICETULUS GRISEUS;

EID: 0031834086     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1998.17.133     Document Type: Article

References (56)

1. Svennerholm L: Chromatographic separation of human brain gangliosides. J Neurochem 1963;10:863-871.
2. Cheresh DA, Pierschbacher MD, Herzig MA, and Mujoo K: Disialogangliosides GD2 and GD3 are involved in extracellular matrix proteins. J Biol Chem 1986;102:688-696.
3. Hokomori S: Aberrant glycosylation in cancer cell membranes as focused on glycolipids: Overview and perspectives. Cancer Res 1985;45:2405-2414.
4. Tsuchida T, Saxton RE, Morton DL, and Irie RF: Gangliosides of human melanoma. J Natl Cancer Inst 1987;78:45-54.
5. Cahan LD, Irie RF, Singh R, Cassidenti A, and Paulson JC: Identification of human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. Proc Natl Acad Sci USA 1982;79:7629-7633.
6. Irie RF, and Ravindranath MH: Gangliosides as targets for monoclonal antibody therapy of cancer. In: Therapeutic Monoclonal Antibody. Borrebaeck C and Larrick J (Eds.), Stockton Press, New York, 1990, pp. 75-94.
7. Irie RF, and Morton DL: Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 1986;83:8694-8698.
8. Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, and Old LJ: Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 1985;82:1242-1246.
9. Saleh MN, Khazaeli MB, Wheeler RH, Dropcho E, Liu T, Urist M, Miller DM, Lawson S, Dixon P, Russel CH, and Lobuglio AF: Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 1992;52:4342-4347.
10. Yamaguchi H, Furukawa K, Fortunato SR, Livingston PO, Lloyd KO, Oettgen HF, and Old LJ: Cell surface antigens of melanoma recognized by human monoclonal antibodies. Proc Natl Acad Sci USA 1987;84:2416-2420.
11. Matsuki T, Sze L, Giuliano AE, and Irie RF: Human monoclonal antibody reacting with sialosylneolactotetraosyl ceramide. Proc Am Assoc Cancer Res 1988;29:A1694.
12. Nasoff MS, Gu M, Galindo J, He X, Mukerjee S, McKnight ME, and Glassy M: Cloning and expression of the human tumor specific antibody GM4. Hybridoma 1997;16:427-439.
13. McKnight ME, Mukerjee S, Nasoff M, Gaskins C, and Glassy M: Isotype-directed enrichment of B cells by magnetic beads in the generation of immunoreactive human monoclonal antibodies. Hybridoma 1996;15:255-261.
14. Glassy M: Immortalization of human lymphocytes from a tumor involved lymph node. Cancer Res 1987;47:5181-5188.
15. Koda K, Glassy M, and Chang H: Generation of human monoclonal antibodies against colon cancer. Arch. Surg 1990;125: 1591-1597.
16. Glassy M: Generation of UC 729-6 and SHFP-1 derived human hybridomas and their growth in serum-free media. J Tissue Cult Meth 1989;12:85-89.
17. Glassy M: Production methods for generating human monoclonal antibodies. Hum Antibod Hybrid 1993;4:154-165.
18. Glassy M, Handley H, Cleveland P, and Royston I: An enzyme immunofiltration assay useful for detecting human monoclonal antibody. J Immunol Meth 1983;58:119-126.
19. Glassy M, and Surh, C: Immunodetection of cell bound antigens using mouse and human monoclonal antibodies. J Immunol Meth 1985;81:115-122.
20. Glassy M, and Cleveland P: Use of mouse and human monoclonal antibodies in enzyme immunofiltration. Meth Enzymol 1986;121:525-541.
21. Gaffar S, Royston I, and Glassy M: Strategies for the design and use of tumor reactive human monoclonal antibodies. Bioessays 1986;4:119-123.
22. Ravindranath MH, Ravindranath RMH, Morton DL, and Graves MC: Factors affecting the fine specificity and sensitivity of serum antiganglioside antibodies in ELISA. J Immunol Meth 1994;169:257-272.
23. Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, and Old JL: GD3, a prominent ganglioside of human melanoma. Detection and characterization by mouse monoclonal antibody. J Exp Med 1982;155:1133-1147.
24. He X, Wikstrand CI, Friedman P, Mansson JE, Svennerholm L, and Bigner DD: GD3 expression by cultured human tumor cells of neuroectodermal origin. Acta Neuropathol 1989;79:317-325.
25. Larrick JW, Danielsson L, Brenner CA, Abrahamson M, Fry KE, and Borrebaeck C: Rapid cloning of rearranged immunoglobulin genes from human hybridoma cells using mixed primers and polymerase chain reaction. Biochem Biophys Res Commun 1989; 160:1250-1256.
26. Kabat EA, Wu TT, Perry HM, Gottesman KS, and Foeller C: Sequences of Protein of Immunological Interest, 5th ed. NIH Publication, Bethesda, MD, 1991.
27. Wahl GM, Lewis KA, Ruiz JC, Routhenberg B, Zhao J, and Evans G: Cosmid vectors for rapid genome walking, restriction mapping, and gene transfer. Proc Natl Acad Sci USA 1987;84:2160-2164.
28. Tomlinson I, Walter G, Marks J, Llewelyn M, and Winter G: The repertoire of human germline VH segments with different hypervariable loops. J Mol Biol 1992;227:776-798.
29. X segments reveals a strong bias in their usage. Eur J Immunol 1994;24:827-836.
30. Mukerjee S, McKnight ME, Nasoff M, and Glassy MC: Co-expression of tumor antigens and their modulation by pleiotropic modifiers enhance targeting of human monoclonal antibodies to pancreatic carcinoma. Hum Antib Hybrid (in press).
31. Bernhard H, Bauerschmitz J, Buschenfelde KH, and Dippold W: Immunorecognition of different ganglioside epitopes on human normal and melanoma tissue. Int J Cancer 1992;51:568.
32. Cheresh DA, Harper JR, Schulz G, and Reisfeld RA: Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci USA 1984;81:5767-5771.
33. Dippold W, Lloyd KO, Li LTC, Ikeda H, Oettgen HF, and Old LJ: Cell surface antigens of human malignant melanoma-definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci USA 1980;77:6114-6118.
34. Hellstrom I, Brankovan V, and Hellstrom KE: Strong anti-tumor activities of IgG3 antibodies to a human melanoma associated ganglioside. Proc Natl Acad Sci USA 1985;82:1499-1502.
35. Nudelman E, Hakomori S, Kannagi R, Levery S, Yen MY, Hellstrom KE, and Hellstrom I: Characterization of a human melanoma associated ganglioside antigen defined by a monoclonal antibody, 4.2. J Biol Chem 1982;257:12752-12756.
36. Bosslet K, Mennel HD, Rodden F, Bauer BL, Wagner F, Altmannsberger A, Sedlacek HH, and Wiegandt H: Monoclonal antibodies against epitopes on the ganglioside GD2 and its lactones: Markers for gliomas and neuroblastomas. Cancer Immunol Immunother 1989;29:171-178.
37. Cheung NKV, Saarinen UM, Neely JE, Landmeier B, Donovan D, and Coccia PF: Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 1985;45:2642-2649.
38. Hirabayashi Y, Hamaoka A, Matsumoto M, Matsubara T, Tagawa M, Wakabayashi S, and Taniguchi T: Syngeneic monoclonal antibody against melanoma antigen with interspecies cross-reactivity recognizes GM3, a prominent ganglioside of B16 melanoma. J Biol Chem 1985;260:13328-13333.
39. Vadhan-Raj S, Cordon-Cardo C, Carswell E, Mintzer D, Dantis L, Duteau C, Templeton MA, Oettgen HF, Old LJ, and Houghton AN: Phase I trials of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: Induction of inflammatory responses at tumor sites. J Clin Oncol 1988;6:1636-1648.
40. Houghton AN, Bajorin DF, and Lonberg M: Treatment of human metastatic melanoma with mouse monoclonal antibodies against GD3 ganglioside. Prog Clin Biol Res 1989;288:383.
41. Caulfield MJ, Bama B, Murthy S, Tubbs R, Sergi J, Medendorp S, and Bukowski RM: Phase Ia-Ib trial of an anti-GD3 monoclonal antibody in combination with interferon alpha in patients with malignant melanoma. J Biol Response Mod 1990;9:319-328.
42. Bajorin DF, Chapman PB, Wong G, Coit DG, Kunicka J, Dimaggio J, Cordon-Cardo C, Urmacher C, Dantis L, Templeton MA, Liu J, Oettgen HF, and Houghton AN: Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer Res 1990;50:7490-7495.
43. Cheung NK, Lazurus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF, and Berger NA: Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987;5:1430-1440.
44. Cheung JK, Burch L, and Kushner BH: Monoclonal antibody 3F8 can effect durable remission in neuroblastoma patient refractory to chemotherapy. A phase II trial. Prog Clin Biol Res 1991;366:395.
45. Cheung NK, Lazurus H, and Miraldi FD: Reassessment of patient response to monoclonal antibody 3F8. J Clin Oncol 1992;10: 671-672.
46. Nishinaka Y, Ravindranath MH, and Irie RF: Development of a human monoclonal antibody to ganglioside GM2 with potential for cancer treatment. Cancer Res 1996;56:5666-5671.
47. Irie RF, and Chandler PJ: Gangliosides recognized by human monoclonal antibody: Targets for immunotherapy of cancer. In: Ganglioside and Cancer Oettgen HF (Eds.). VCH Verlagsgesellschaft, New York, 1989, pp. 249-257.
48. Ravindranath MH, Tsuchida T, Morton DL, and Irie RF: Ganglioside GM3:GD3 ratio as an index for the management of melanoma. Cancer 1991;67:3029-3035.
49. Wu ZL, Schwartz E, Seeger R, and Ladisch S: Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res 1986;46:440-443.
50. Berra B, Giani SM, and Riboni L: Correlation between ganglioside distribution and histological grading of human astrocytomas. Int J Cancer 1985;36:363-366.
51. Eto Y, and Shinoda S: Gangliosides and neutral glycosphingolipids in human brain tumors: Specificity and their significance. Adv Exp Med Biol 1982;152:279-290.
52. Fredman P, Holst HV, Collins VP, Amman A, Dellheden B, Wahren B, Granholm L, and Svennerholm L: Potential ganglioside antigens associated with human gliomas. Neurol Res 1986; 8:123-126.
53. Kemshead A, Walsh F, Pritchard J, and Greaves M: Monoclonal antibody to ganglioside GQ discriminates between haematopoietic cells and infiltrating neuroblastoma tumor cells in bone marrow. Br J Cancer 1987;27:447-452.
54. Glassy MC, and Ferrone S: Differential segregation patterns of human chromosomes in somatic cell hybrids constructed with human B lymphocytes and human melanoma cells. Cancer Res 1982;42:3971-3973.
55. Glassy MC, Handley HH, Surh C, and Royston I: Genetically stable human hybridomas secreting tumor reactive human monoclonal IgM. Cancer Invest 1987;5:449-457.
56. Thammana P, and Scharff M: Immunoglobulin heavy chain class switch from IgM and IgM in a hybridoma. Eur J Immunol 1983;13:514-519.